| Autor: |
Alimohammadi, Reza, Porgoo, Meysam, Eftekhary, Mohamad, Kiaie, Seyed Hossein, Ansari Dezfouli, Ehsan, Dehghani, Maryam, Nasrollahi, Kaveh, Malekshahabi, Talieh, Heidari, Maryam, Pouya, Sedigheh, Alimohammadi, Masoumeh, Sattari Khavas, Dorsa, Modaresi, Mohammad Sadra, Ghasemi, Mohammad Hossein, Ramyar, Hamed, Mohammadipour, Fatemeh, Hamzelouei, Fateme, Mofayezi, Ahmadreza, Mottaghi, Seyed Saeed, Rahmati, Amirhosein |
| Předmět: |
|
| Zdroj: |
NPJ Vaccines; 9/2/2022, Vol. 7 Issue 1, p1-12, 12p |
| Abstrakt: |
At the forefront of biopharmaceutical industry, the messenger RNA (mRNA) technology offers a flexible and scalable platform to address the urgent need for world-wide immunization in pandemic situations. This strategic powerful platform has recently been used to immunize millions of people proving both of safety and highest level of clinical efficacy against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we provide preclinical report of COReNAPCIN®; a vaccine candidate against SARS-CoV-2 infection. COReNAPCIN® is a nucleoside modified mRNA-based vaccine formulated in lipid nanoparticles (LNPs) for encoding the full-length prefusion stabilized SARS-CoV-2 spike glycoprotein on the cell surface. Vaccination of C57BL/6 and BALB/c mice and rhesus macaque with COReNAPCIN® induced strong humoral responses with high titers of virus-binding and neutralizing antibodies. Upon vaccination, a robust SARS-CoV-2 specific cellular immunity was also observed in both mice and non-human primate models. Additionally, vaccination protected rhesus macaques from symptomatic SARS-CoV-2 infection and pathological damage to the lung upon challenging the animals with high viral loads of up to 2 × 108 live viral particles. Overall, our data provide supporting evidence for COReNAPCIN® as a potent vaccine candidate against SARS-CoV-2 infection for clinical studies. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink